Wenran Zhao
About Wenran Zhao
Wenran Zhao is the Strategy & Operations Lead for the Hematology Business Unit at Bristol Myers Squibb in Shanghai, China. He has extensive experience in strategic planning, project management, and brand campaign management within the pharmaceutical industry.
Title
Wenran Zhao currently holds the position of Strategy & Operations Lead in the Hematology Business Unit at Bristol Myers Squibb, based in Shanghai, China.
Current Role at Bristol Myers Squibb
Wenran Zhao is the Strategy & Operations Lead for the Hematology Business Unit at Bristol Myers Squibb. Based in Shanghai, China, his role involves strategic planning and operations management specifically tailored to the hematology sector.
Previous Roles at GSK and BeiGene
Before joining Bristol Myers Squibb, Wenran Zhao worked at GSK as the Strategy & PMO Senior Manager for three months in 2019-2020 and at BeiGene as the Senior New Product Introduction & Strategic Planning Manager also for three months in 2019, both positions were based in Shanghai.
Experience at 罗氏公司 and Syngenta
From 2015 to 2019, Wenran Zhao served as the Senior Strategic Project Manager for Hematology at 罗氏公司 in Shanghai. Prior to that, he was the Sales Capability Manager at Syngenta from 2010 to 2015, also in Shanghai.
Education and Early Career at Deloitte
Wenran Zhao obtained his Bachelor's degree in Financial Statistics from the Shanghai University of Finance and Economics, where he studied from 2004 to 2008. He then began his career at Deloitte in Shanghai, working as a Consultant from 2008 to 2010.
Project Leadership and Campaign Management
Wenran Zhao has led the GQCE readiness project, developing post-GQCE strategies and optimal pricing schemes. He also has extensive experience in managing brand campaigns including patient flow clarification, leverage point identification, campaign design, and communication to field force.
Product Launch and Alliance Management
Wenran Zhao played a key role in the launch readiness of a new product for hemophilia A, managing alliances related to the product. He also developed and implemented biosimilar defense strategies and coordinated product line extensions in the hematology business unit.